More and more companies are joining forces with software developers to create innovative products. But many are learning the hard way that making next-generation digital therapeutics isn’t as easy as signing a partnership agreement.
Andrew Fraser
Advertisement
Andrew Fraser is a director in Digital and Emerging Technology practice and leads the Digital Transformation team at Guidehouse.
Articles by Andrew Fraser
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Enters $4.7 Billion Definitive Agreement with Akero Therapeutics
2
FDA Approves Libtayo for Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma
3
Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform
4
The Situation We Faced: The Development and Commercialization of MariTide
5
